Telomir Pharmaceuticals, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TELO research report →
Range $4 – $4
Price Chart
About the company
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound.
- CEO
- Erez Aminov
- IPO
- 2024
- Employees
- 2
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on TELO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.82M
- P/E
- -0.28
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 6.61
- EV/EBITDA
- -4.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -107.89%
- ROIC
- -129.09%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-10,538,849
- Net Income
- $-10,413,205+37.0%
- EPS
- $-0.33+41.1%
- OCF Growth
- +27.3%
- FCF Growth
- +27.3%
- 52W High
- $1.58
- 52W Low
- $0.36
- 50D MA
- $0.98
- 200D MA
- $1.18
- Beta
- -0.25
- RSI (14)
- 15
- Avg Volume
- 122.82K
No earnings-call transcripts are available for TELO yet.
- Free Float
- 57.1%
- Shares Outstanding
- 73.68M
- Float Shares
- 42.04M
of shares held by institutions
32 13F filers
Buy/sell ratio 1.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1.61M | 0 |
| Vanguard Group Inc | 1.14M | ▲ 35.71K |
| Geode Capital Management, LLC | 438.26K | ▲ 99.39K |
| Blackrock, Inc. | 364.38K | ▲ 83.91K |
| Vanguard Fiduciary Trust Co | 282.29K | ▲ 56.99K |
| Citadel Advisors LLC | 146.43K | ▲ 133.16K |
| Northern Trust Corp | 104.89K | ▲ 43.36K |
| State Street Corp | 58.60K | 0 |
| Bank Of New York Mellon Corp | 51.45K | 0 |
| Captrust Financial Advisors | 51.19K | 0 |
| World Investment Advisors | 37.04K | 0 |
| Osaic Holdings, Inc. | 30.99K | ▼ 10.50K |
Held by 26 ETFs
Biggest fund positions in TELO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Whalen Matthew Pratt | other | 50,000 |
| Apr 16, 26 | MacPherson Edward Clouston | other | 50,000 |
| Apr 16, 26 | Del Giudice Matthew Paul | other | 50,000 |
| Jun 3, 26 | Mushak Andriy | other | 0 |
| May 21, 26 | Aminov Erez | other | 2,000,000 |
| May 21, 26 | Aminov Erez | other | 1,960,170 |
| May 21, 26 | Aminov Erez | sell | 1,960,170 |
| May 21, 26 | Aminov Erez | sell | 2,000,000 |
| May 21, 26 | Whalen Matthew Pratt | other | 25,000 |
| May 21, 26 | Whalen Matthew Pratt | sell | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TELO coverage
Recent articles, reports, and earnings notes.
No research on TELO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TELO report →Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
globenewswire.com · Nov 18
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
newsfilecorp.com · Oct 29
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
globenewswire.com · Oct 6
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
newsfilecorp.com · Sep 29
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
globenewswire.com · Sep 17
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
globenewswire.com · Sep 14
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?
defenseworld.net · Aug 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.